Nucleophosmin (NPM), a multifunctional nucleolar phosphoprotein is dysregulated in human malignancies leading to anti-apoptosis and inhibition of differentiation.
Introduction
Nucleophosmin (NPM), also known as B23, NO38 or numatrin (Lim and Wang, 2006) , is a nucleolar phosphoprotein composed of an N-terminal globular domain (1-110 residues) and a C-terminal domain (111-294 residues) rich in acidic residues. NPM was initially identified as a critical player in ribosome biogenesis (Lim and Wang, 2006) . Since then a number of cellular activities associated with NPM indicates that this protein has multiple functions, especially in cell proliferation, cytoplasmic/nuclear shuttle transportation, nucleic acid binding, ribonucleic cleavage, centrosome duplication and molecular chaperoning (Okuwaki et al., 2001; Okuda, 2002; Ye, 2005) . NPM shuttles between the nucleolus and the cytoplasm, and it also translocates from the nucleolus to the nucleoplasm during the stationary phase of growth or during treatment with certain antitumor drugs (Yung et al., 1990; Chou and Yung, 1995) . Under native condition, NPM exists as an oligomer (Herrera et al., 1996; Namboodiri et al., 2004) . The structural features of NPM consist of an oligomerization domain, a metal-binding motif, a bipartite nuclear localization signal, phosphorylation sites and a nucleolar localization signal (Wang et al., 1993; Wang et al., 2005) . Mounting evidence supports that NPM interacts with a variety of proteins including nucleolin (Li et al., 1996) , cell cycle-related protein p120 (Valdez et al., 1994) , human immunodeficiency virus (HIV)-1 Rev protein (Fankhauser et al., 1991) , Human MDM2 (HDM2) (Kurki et al., 2004) , tumor suppressor ARF (Itahana et al., 2003; Bertwistle et al., 2004; Korgaonkar et al., 2005) , p53 (Colombo et al., 2002; Li et al., 2004; Maiguel et al., 2004) and pRb (Takemura et al., 1999) .
Nucleophosmin is found to be more abundant in tumor and growing cells than that in normal resting cells (Feuerstein et al., 1988; Chan et al., 1989) . In fact, NPM has been proposed as a tumor marker for prostate (Subong et al., 1999) , colon (Nozawa et al., 1996) , ovarian (Shields et al., 1997) , gastric (Tanaka et al., 1992) and bladder (Yeh et al., 2006) cancers because NPM expression is markedly higher in these tumor cells than that in the corresponding normal cells. Notably, overexpression of NPM in NIH3T3 cells results in malignant transformation (Kondo et al., 1997) . NPM expression is downregulated in cells undergoing differentiation or apoptosis (Patterson et al., 1995; van Belzen et al., 1995) . However, overexpression of NPM leads to the inhibition of apoptotic cell death (Ye, 2005; Grisendi et al., 2006) . In addition, NPM is frequently found in chromosomal translocations associated with hematological malignancies (Naoe et al., 2006) . The role of NPM as an oncogene is further enhanced as it binds several tumor suppressor genes, including pRb (Takemura et al., 1999), p14 ARF (Brady et al., 2004; Zhang, 2004; Lee et al., 2005; Gjerset, 2006) and p53 (Colombo et al., 2002; Li et al., 2004; Maiguel et al., 2004) ARF localization and compete with Hdm2 for ARF association. NPM knockdown markedly enhances ARF-Mdm2 association and diminishes ARF nucleolar localization. In addition, it has been shown that NPM directly interacts with p53 and downregulates its transcriptional activity (Maiguel et al., 2004) . NPM binds to the p53 N-terminal end and prevents p53 phosphorylation at Ser15 in response to low doses of UV radiation. However, downregulation of NPM by small interfering RNA allowed p53 phosphorylation to occur. Similar results were observed in hematopoietic cells following ionizing irradiation treatments (Li et al., 2005) and in lymphoblasts exposed to hypoxia (Li et al., 2004) . Together these data indicate that NPM is a natural repressor of p53 that may contribute to dampening p53 function during cellular growth or in the presence of DNA damage.
Hence, NPM is an oncoprotein that if selectively targeted would be a potential therapy for cancer. As proof-of-concept, a peptide derived from the Rev protein that binds to NPM leads to cytotoxicity in Ras-transformed NIH-3T3 (Ras-3T3) cells that also inhibits tumor growth in a nude mouse model . In this study, we identified a putative small molecular inhibitor (SMI) NSC348884 which targets NPM dimer formation. NSC348884 has efficient cytotoxicity on several different cancer cell lines by upregulating p53 and inducing apoptosis. Therefore targeting NPM by NSC348884 may be a potential cancer therapy alone or in combination with chemotherapy.
Results
Structure-based discovery of small molecular inhibitors of NPM Nucleophosmin forms dimers and higher oligomers via its N-terminal globular domain (residues, 1-110) ( Figure 1a , Hingorani et al., 2000) . We hypothesized that an SMI, targeting protein-protein interactions of the dimer interface would inhibit NPM function. Since there is no crystal structure available for human NPM, a homology model of human NPM was built according to the Xenopus NO38-core chaperone structure (residues, 1-107) (pdb:1XE0) (Namboodiri et al., 2004) , which has a sequence identity of 77% and similarity of >90%. The homology model of NPM demonstrated a highly conserved topology and sidechain interactions of the dimer interface in comparison to Xenopus NO38-core structure. Inspection of the subunit interface reveals a predominantly hydrophobic-aromatic interaction that promotes the formation of a dimer and pentamer. Residues Tyr6, Lue7, Phe20, His29, Met53, Tyr55 and His104 are intimately involved in dimer formation and are essentially conserved except for Tyr6 (Phe) and Met 53 (Ile) in Xenopus (NO38), which are conservative changes (Figure 1b) . The two histidines and three aromatic residues form a hydrophobic interaction network was exploited for disruption by a specific SMI. A 'pharmacophore' based in silico screen of a large small molecular library ('Unity' search in Sybyl 7.3) identified several putative small molecules of which NSC348884 (di-[((6-methyl-1H-benzo[d] imidazol-2-yl)methyl)((5-methyl-3-oxo-3H-indol-2-yl)methyl)]) aminoethane; molecular mass, 637.0 g mol
À1
) was the top hit that docked with excellent hydrogen bonding and hydrophobic interactions (Figures 1c and d ).
NSC348884 disrupts NPM oligomer formation
To examine whether NSC348884 specifically interacts with NPM and disrupts its oligomer formation, LNCaP and HCT116 cells with wild-type NPM (no translocations) were treated with varying concentrations of NSC348884 (0, 5 and 6 mM) for 24 h, lysed under nondenaturing conditions and analysed by native polyacrylamide gel electrophoresis (PAGE) which is an excellent tool for detecting oligomers and aggregates since the protein retains its folded conformation. We utilized 14-3-3 which forms dimers as a control. Figure 2 shows that in both LNCaP and HCT116 cells, the NPM oligomer is disrupted with the formation of NPM monomers (Figures 2a, c and e) at 5 and 6 mM NSC348884, with no effect on the 14-3-3 dimer formation (Mr B60 kDa) (Figure 2b ) in these cells. The two bands shown in HCT116 represent different isoforms of 14-3-3 proteins. Taken together, NSC348884 is able to bind to NPM and interfere with oligomer formation of NPM specifically.
Inhibition of NPM is cytotoxic and synergizes with doxorubicin Nucleophosmin plays an essential role in cellular activities such as ribosome biogenesis, cell proliferation, apoptosis and centrosome duplication. Therefore, inhibition of NPM should affect cell growth. To determine the effect of NPM inhibitor NSC348884 on cancer cell proliferation, cell viability assays were conducted on LNCaP and Granta (human mantle cell lymphoma) cells with varying concentrations of NSC348884 over 4 days. In LNCaP cells, the IC 50 for cell viability was B4 mM (Figure 3a) , while for all the three Granta cell lines the IC 50 was B1.7 mM (Figure 3a) . The difference in IC 50 is attributed to the differential proliferative capacity of the two types of cancer cell lines.
Since Rev peptide binds to NPM and potentates the doxorubicin-induced decrease of cellular viability and inhibition of tumor growth in nude mice , we evaluated if NSC348884 would be additive or synergistic with doxorubicin, a therapy commonly used in this disease. An IC 50 of 0.01-0.02 mM for doxorubicin was established for all three Granta cell lines, while at 0.1 nM doxorubicin had no effect on cell viability ( Figure 3a ). As seen in Figure 3a , 1 mM NSC348884 had no effect on cell viability at 4 days in a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. However, when all three Granta cell lines are exposed to 1 mM NSC348884 and 0.1 nM doxorubicin, there was exquisite synergy with nearly complete loss of cell viability (Figure 3b ). N-terminal residues (1-110) form the dimerization/oligomerization domain; residues 111-189 form the histone-binding domain; residues 190-294 form the DNA-/RNA-binding domain. Within these domains reside functional motifs for nuclear export signaling, the acidic domain, bipartite nuclear localization signaling, the basic cluster and nucleolar localization signaling. (b) Structure-based sequence alignment of human NPM with Xenopus NO38-core (pdb:1XE0) sequence predicts for a highly conserved N-terminal NPM domain. The residues in red (Y6, L7, F20, H29, M53, Y55, H104) are intimately involved in dimer formation and are essentially conserved except for residue F6 and I53 in Xenopus which are conservative changes (blue). (c) Homology model of human NPM Nterminal domain shows a highly conserved topology and interface predominantly of hydrophobic-aromatic interactions that promotes the formation of a dimer and pentamer. NSC348884 a putative NPM inhibitor binds at the dimer interface and interferes with dimerization. (d) Detailed interactions that NSC348884 makes with NPM are two hydrogen bonds with the backbone carbonyls of L7 and K21, an aromatic-aromatic interaction with Y6 and a potential hydrogen bond interaction with D25. See online version for color figure.
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NSC348884 induces apoptosis
It has been reported that NPM prevents apoptosis (Ye, 2005; Grisendi et al., 2006) . To examine whether disruption of NPM by NSC348884 correlates to apoptotic cell death, several cancer cell lines were treated with NSC348884 and apoptosis was determined by different methods. Treatment of LNCaP cells with varying concentrations of NSC348884 (0-5 mM) showed a dose-dependent increase in apoptosis by morphology assay (Figure 4a ). Apoptosis by morphology was marked (>50%) at an exposure of 4 and 5 mM NSC348884 which correlated well with poly(ADPribose) polymerase (PARP) cleavage and induction H2AX phosphorylation (Liu et al., 2007) on Ser139 ( Figure 4b ). Hence, together the data support the notion that apoptosis is completed at 24 h at a dose of 4-5 mM NSC348884, which appears the mirror the IC 50 for cell viability (Figure 3a) . Furthermore, apoptosis induced by NSC348884 was confirmed by annexin V staining and flow cytometry analysis. As shown in Figure 4c , NSC348884 induced apoptosis in several different cancer cell lines as evident by an increase in annexin V binding, which indicates phosphatidylserine translocation to the outer membrane. Collectively, these data demonstrate that NPM inhibitor, NSC348884 inhibits cell proliferation and promotes apoptosis in a variety of cancer cell lines.
NSC348884 upregulates p53
Mounting evidence indicate that NPM negatively regulates tumor suppressor p53 through interaction with p53 directly to prevent its phosphorylation on Ser15 (Maiguel et al., 2004) or through binding with p14 ARF to impair the ARF-Hdm2 association and increase Hdm2/p53 complex formation (Gjerset, 2006) . NPM knockdown by small interfering RNA enhances p53 phosphorylation and transcriptional activity. Therefore, inhibition of NPM by NSC348884 could affect p53 status. To address this, LNCaP cells were untreated and treated with different dosage of NSC348884 for 2-24 h, and the changes in p53 protein and phosphorylation levels were determined by western blot. Indeed, NSC348884 increased both p53 protein level and phosphorylation on Ser15 in a dose-dependent manner after 2 h of (Figure 5a) . Moreover, p21, a key transcriptional target of p53 was also upregulated by NSC348884 (Figure 5b ), suggesting inhibition of NPM elevated p53 transcriptional activity. Similarly, NSC348884 also enhanced p53 in breast cancer cell line MCF7 (data not shown). Consistent with this, immunocytochemistry staining showed that higher p53 proteins were induced by NSC348884 treatment compared to vehicle in LNCaP and A549 cancer cells (Figure 5c ). Moreover, the p53 signals were located in the nucleus, suggesting p53 has functions after NSC348884 treatment. 
Discussion
Nucleophosmin functions as an oncoprotein in certain cellular contexts and may be an important molecular target for cancer therapy. To our knowledge, the only example of an inhibitor of NPM is a peptide derived from the Rev protein (HIV) that binds to NPM and leads to cytotoxicity of Ras-3T3 cells and tumors in a nude mouse model . NSC348884 is the first putative SMI to target NPM discovered utilizing a structure-based design approach that disrupts dimer/oligomer formation. Similar to the inhibition of NPM by the Rev peptide and the downregulation of NPM by small interfering RNA, NSC348884, by binding and blocking the function(s) of NPM, induces apoptosis, upregulates p53 and sensitizes cancer cells to doxorubicin treatment at subclinical doses.
Targeting protein-protein interaction sites as potential intervention points or 'hot spots' for the development of anticancer agents have made clear inroads and at 1 mM or doxorubicin at 0.1 nM had no effect on cell viability but together was synergistic on all three Granta cell lines with near complete loss of viability, *Po0.003.
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are now a reality (Arkin and Wells, 2004) . This is due to the discovery of several specific small molecular agents targeting anti-apoptotic targets such as Bcl-2-Bax (Oltersdorf et al., 2005) , MDM2-p53 (Vassilev et al., 2004) and XIAP-SMAC (Oost et al., 2004) . Under native condition, NPM exists as oligomers via its Nterminal molecular chaperone domain (Herrera et al., 1996; Hingorani et al., 2000; Namboodiri et al., 2004) . We hypothesized that a specific SMI that disrupts the formation of oligomers would inhibit NPM function(s) in cancer cells. In order to target human NPM with an SMI, we evaluated the precise three-dimensional structure of NPM based on the highly conserved three-dimensional structure of Xenopus NO38 and its requirement to form dimers and pentamers via its Nterminal domain (residues, 1-110). We utilized molecular modeling, pharmacophore design, in silico screening of large databases and interactive docking to identify several putative NPM inhibitors that disrupt a defined hydrophobic pocket required for dimerization (Figure 1) . One of the compounds NSC348884 was selected and as predicted by modeling and interactive docking studies, disrupted NPM oligomer formation determined by native PAGE (Figure 2 ). Therefore, we have developed a rapid, rational and reliable method that is recursive in the discovery of novel drugs for cancer therapy. Overexpression of NPM prevents apoptosis induced by a variety of stimuli including hypoxia, radiation and retinoic acid (Ye, 2005; Grisendi et al., 2006) . NPM is rapidly upregulated after UV irradiation resulting in resistance to UV-mediated apoptosis through enhanced DNA repair (Grisendi et al., 2006) . As a nuclear PI(3,4,5)P 3 receptor, NPM inhibits DNA fragmentation activity of caspase-activated-DNase and mediates an anti-apoptotic effect of nerve growth factor (Ahn et al., 2005) . In addition, NPM is found to target the interferon-inducible, double-stranded RNA-dependent protein kinase and inhibit apoptosis (Grisendi et al., 2006) . However, downregulation of NPM potentiates apoptotic cell death (Ye, 2005) . In this regard, we have shown NSC348884 to induce apoptosis in several types of cancer cells even in the absence of other stressful events (Figure 4) . A mouse NPM knockout experiment demonstrated that lack of NPM expression results in accumulation of DNA damage (Colombo et al., 2005) . Apoptosis induced by NSC348884 may be involved in mediating increased DNA damage.
Normally, the expression of cellular p53 protein is very low due to its relatively short half-life. Human MDM2 (HDM2) regulates p53 levels by binding to p53 and initiating proteasomal degradation (Oren, 1999 
NSC348884 * * * ARF to the nucleoplasm, where it interacts with HDM2 and prevents p53 degradation (Bertwistle et al., 2004; Korgaonkar et al., 2005; Lee et al., 2005; Gjerset, 2006) . In addition, NPM has been shown to interact with the p53 N-terminal domain directly and inhibits p53 phosphorylation on Ser15 in response to low doses of UV radiation (Colombo et al., 2002; Maiguel et al., 2004) . Collectively the data indicate that NPM is a natural repressor of p53 that may contribute to dampening of p53 function during cellular growth or in the presence of low levels of DNA damage. In contrast, contradictory reports indicate that NPM stabilizes p53 by binding to HDM2 and protecting p53 from HDM2-mediated degradation (Kurki et al., 2004) . Our data suggest that NPM suppresses p53 and blockage of NPM by NSC348884 enhances p53 activity ( Figure 5 ). The mechanism of p53 upregulation by NSC348884 is currently being investigated.
In conclusion, using molecular modeling, pharmacophore design, in silico screening and interactive docking, we have successfully selected an SMI of NPM (NSC348884). The effect of NSC348884 on growth inhibition is observed in many different cancer cell lines with distinct IC 50 for cell viability based on the proliferative rate. Importantly, NSC348884 treatment sensitizes cells to doxorubicin and provides an excellent opportunity for combination therapies with lower doses of both drugs. Thus, targeting NPM by NSC348884 represents a potentially useful approach to anticancer therapy.
Materials and methods
Homology modeling, pharmacophore design, in silico screening and drug discovery NPM forms dimers and higher oligomers via its N-terminal globular domain (amino-acid residues, 1-110). Since there is no crystal structure available for human NPM, a homology model of the human NPM was built utilizing 'Modeller' on a Linux workstation (http://salilab.org/modeller) utilizing the highly homologous Xenopus NO38-core chaperone structure (pdb:1XE0) (Namboodiri et al., 2004) . The model was energy minimized (Sybyl V7.3, Tripos, MO, USA) and analysed by Procheck V3.5 (http://www.biochem.ucl.ac.uk/Broman/ procheck) and Ramachandran plot for correctness and outliers. Inspection of the human NPM homology model showed that 
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W Qi et al the dimer interface revealed a highly conserved well-defined hydrophobic-aromatic pocket. We utilized the aromatic hydrophobic interactions between the NPM dimer to design a 'pharmacophore' to disrupt the dimer and hence NPM function. Several large small molecular databases (NCI, Maybridge, LeadQuest and the Available Chemical Database) were screened using a 'Unity' search in Sybyl V7.3. The top hits were interactively docked utilizing FlexX (Sybyl V7.3), ranked and interactions analysed with respect to affinity of binding (T and C scores) and energy of binding (X score).
Cells and reagents
Human cancer cell lines used in this study include prostate (LNCaP, PC3, DU145), colon (HCT116), lung (A549), breast (MCF7) purchased from American Type Culture Collection (Rockville, MD, USA) and mantle cell lymphoma were maintained in RPMI 1640 medium (Mediatech, Manassas, VA, USA) supplemented with 10% fetal bovine serum, 2 mM sodium pyruvate and 100 U ml
À1
penicillin/streptomycin at 37 1C in a humidified atmosphere of 5% CO 2 . Anti-NPM/B23 (C-19), anti-PARP (H-250), anti-p21 (F-5) and anti-14-3-3 (H-8) antibodies were obtained from Santa Cruz (Santa Cruz, CA, USA). Anti-p53 (DO-1) antibody was from Calbiochem (San Diego, CA, USA). Anti-phospho-p53 (Ser15) was from Cell Signaling (Danvers, MA, USA). Anti-phospho-H2AX (Ser139) was purchased from Upstate (Lake pacific, NY, USA). Anti-b-actin antibody and 4 0 -6-diamidino-2-phenylindole (DAPI) were from Sigma (St Louis, MO, USA).
Cell viability assays
LNCaP, Granta-4, -22 and -519 cell lines were seeded into 96-well tissue culture plates with 50 000 cells per well, cultured for 24 h and exposed to NSC348884, doxorubicin or combination for 4 days. All studies were performed in triplicate and were repeated three different times. After incubation, 20 ml of 2 mg ml À1 , MTT were added to each well and incubated an additional 4 h. The media and MTT dye were aspirated, and 100 ml dimethyl sulfoxide (DMSO) was added to each well, absorbance was read at 540 nm on a plate reader (Wallac Victor; PerkinElmer, Waltham, MA, USA). Data were expressed as the percent survival of control calculated from the absorbance and corrected for background.
Apoptosis assays
Drug-treated LNCaP cells were examined for apoptotic morphology using a fluorescence staining technique as described previously (Qi and Martinez, 2003) . Briefly, cells were exposed to DMSO or 1-5 mM of NSC348884 for 24 h and were harvested by trypsinization. After staining with a mixed dye solution containing 100 mg ml À1 each of acridine orange and ethidium bromide the morphology of the cells were observed by fluorescence microscopy, and the number of apoptotic cells was quantified. Studies were performed in triplicate and mean ± s.d. calculated. In all cases, a minimum of 200 cells were counted for each sample.
Using annexin V staining to detect apoptosis, treated MCF-7, PC-3, DU145 and Granta (-519, -4, -22) cells were harvested by trypsinization and rinsed with cold phosphate-buffered saline (PBS) once. After centrifugation for 5 min, cancer cells were resuspended in 500 ml of 1 Â annexin V binding buffer (Annexin V-FITC Reagent Kit, cat.no. 1001-1000, BioVision, Mountain View, CA, USA) and then added 1 ml of annexin V-FITC and 1 ml of Propidium Iodide (Annexin V-FITC Reagent Kit, BioVision). After incubation for 5 min at room temperature in the dark, the samples were analysed by flow cytometry.
Immunocytochemistry
LNCaP, A549 or HCT116 cells grown on cover slips were treated with DMSO or 5 mM of NSC348884 for 6 h and then fixed in cold methanol:acetone (3:7) for 5 min. The cover slips were washed twice with cold PBS and blocked with blocking buffer (1% bovine serum albumin, 0.01% saponin and 1% normal mouse serum in PBS) for 1 h at room temperature. The cover slips were then immunostained using anti-p53 antibody at the dilution 1:100 in blocking buffer overnight at 4 1C. After washing three times with PBS, the secondary antibody conjugated with Cy3 (Sigma) was applied for 30 min at room temperature. The cover slips were washed three times by PBS and counterstained by DAPI (0.1 mg ml À1 ) for 1 min. Finally, the signal was checked using florescence microscopy. Primary or secondary antibody replacement with normal serum from the same animal species was used as the negative controls.
Immunoblotting
LNCaP or HCT116 cells were lysed in NP-40 lysis buffer containing 50 mM Tris-Cl (pH 7.4), 0.15 M NaCl, 0.5% NP-40, 1 mM dithiothreitol, 50 mM sodium fluoride and 2 ml ml À1 of a protease inhibitor cocktail (Sigma). Protein concentrations were determined using the protein assay kit (Bio-Rad, Hercules, CA, USA) and 50 mg of protein was resolved by electrophoresis on a 10% SDS-polyacrylamide gel electrophoresis (PAGE). The proteins were then transferred onto a nitrocellulose membrane and nonspecific binding was blocked by incubating with 5% nonfat milk in Tris-buffered saline Tween-20 buffer (0.01 M Tris-Cl, pH 8.0, 0.15 M NaCl, 0.5% Tween-20) at room temperature for 1 h. The membrane was subjected to the indicated antibodies and the proteins were detected by the SuperSignal West Pico detection system (Pierce, Rockford, IL, USA). For native PAGE gel experiment, the samples were not denatured by heating and the electrophoresis was run in the absence of SDS.
Statistical analysis
Statistical comparisons were performed by Student's twotailed t-test. Po0.05 was considered to be significant.
